Repligen deal

RGEN terminated its arrangements with Repligen Clinical Partners L.P. regarding the development and marketing of the partnership's recombinant Platelet Factor-4 (rPF4) program. Rights to rPF4 remain with the partnership, which was formed in 1992 to finance the clinical testing and commercial development of rPF4. ...